In 6 months time our pipeline could show successful trof P2 (Fragile X) and P3 (Retts) trials and NNZ-2591 P2 trials underway in Angelman, Phelan-McDermid and Pitt Hopkins. Obvsiously, P3 retts success would be very encouring for NNZ-2591. If we are in that position we would be a very, very attractive takeover target.
Ann: Positive FDA meetings enable INDs for three Phase 2 trials, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.29 |
Change
0.660(3.97%) |
Mkt cap ! $2.177B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $9.078M | 529.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1334 | $17.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.33 | 2245 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |